Market Access, value dossiers and health technology assessment
Demonstrating the value of a health technology means connecting the decision problem with the best available evidence.
Access and health technology assessment raise questions that extend beyond the efficacy observed in one study. Which comparators matter? In which patient populations? For which clinical outcomes? How certain are the estimates, and what remains unknown? Answering these questions calls for a coherent evidence strategy, explicit methods and rigorous scientific communication.
Heorfy provides methodological, biostatistical and evidence-synthesis support for projects in Market Access and Health Technology Assessment (HTA). This expertise can contribute to wider assignments led by market access teams, consultancies or health technology developers.
How Heorfy can contribute
Specific scientific capabilities, tailored to each study design and project objective.
Value dossiers
Scientific structuring and synthesis of available clinical and economic evidence.
Systematic reviews and meta-analysis
Study identification, critical appraisal and quantitative synthesis.
Indirect treatment comparisons
Network meta-analysis, comparisons and assessment of assumptions.
PICO development
Defining relevant populations, interventions, comparators and outcomes.
Analytical support for JCA
Statistical and methodological contributions to joint clinical assessments.
HTA evidence reports
Transparent presentation of findings, uncertainty and limitations.
Value dossiers grounded in traceable evidence
A value dossier brings together the unmet health need, clinical context, comparative evidence, patient- and system-relevant outcomes and, where appropriate, economic information. Its strength depends less on document length than on the logic, consistency and traceability of its claims.
Scientific contributions may include framing evidence questions, critically evaluating studies, organising findings, developing methodological sections and producing analyses to support specific arguments. Requirements and format must reflect the jurisdiction, intended audience and purpose of the dossier.
Evidence synthesis and comparisons across alternatives
When multiple studies are available, meaningful synthesis requires appropriate systematic searching, explicit eligibility criteria and careful appraisal of risk of bias and heterogeneity. Meta-analysis is not a mechanical exercise: it must answer a relevant question and respect the clinical and methodological comparability of the underlying evidence.
When direct head-to-head evidence is insufficient, indirect treatment comparisons or network meta-analysis may be appropriate, subject to assumptions such as transitivity, consistency and the characteristics of the available studies. Confidence in the conclusions depends both on evidence quality and on the limitations of the chosen method.
Methodological support for Joint Clinical Assessments
European Joint Clinical Assessments (JCAs) require a rigorous account of comparative clinical evidence relating to patient populations, interventions, comparators and health outcomes. A JCA is not an economic evaluation, nor does it replace national pricing and reimbursement decisions.
Heorfy can provide statistical analysis and scientific support for defined tasks, including structuring PICO questions, assessing available evidence, quantitative synthesis and critical appraisal of direct and indirect comparisons. The scope must reflect current methodological requirements. Projects involving full coordination or formal dossier submission should draw on the broader regulatory and HTA expertise required.
Specialist input within a wider access strategy
Heorfy brings together biostatistics, study methodology and health economic evaluation to support consistency between evidence generation, synthesis and interpretation. Collaboration may focus on a literature review, comparative analysis, technical section of a value dossier or a defined work package within a larger programme.